Literature DB >> 20872377

Older donors and older recipients in kidney transplantation.

Giovanni Stallone1, Barbara Infante, Loreto Gesualdo.   

Abstract

Over the last 2 decades, while kidney transplantation became the therapy of choice for end-stage renal disease, the increasing gap between the limited supply of cadaveric donors and the rising demand for kidneys led to the consideration of alternative strategies to provide more organs for transplant. The significant increase of mean donor age suggested the use of kidneys from older donors. In addition, an increasing number of donors with significant comorbidities (e.g., hypertension and diabetes) or deceased due to stroke have been used since the early 1990s, leading to the definition of the fuzzy and disputed concept of "marginal" donors. Such organs are eligible for organ donation but, because of extreme age and other clinical characteristics, are expected to produce allografts at risk for diminished posttransplant function. Thus, the challenge is now to improve the graft outcome gap between patients receiving grafts from "marginal" and "optimal" donors. This implies appropriate transplantation strategies during all transplant phases, including reduction of cold ischemia time, recipient selection, adaptation of immunosuppressive drug regimens, increase in nephron mass by dual kidney transplantation and improvement in the graft selection process using histological criteria. This review summarizes the current definition of a marginal donor and provides some suggestions for clinical management of these particular kidney transplants. We believe that in this particular transplanted population, an effective balance should be ensured between maintaining graft survival, reducing the impact of immunosuppressive toxicity and maximizing patient quality of life through the reduced incidence of cardiovascular disease and malignancies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20872377

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  5 in total

1.  Aging and transplantation - a topic for biomedicine or bioethics?

Authors:  William J Hubbard; Nassrin Dashti
Journal:  Aging Dis       Date:  2011-02-22       Impact factor: 6.745

2.  Detrimental effects of rat mesenchymal stromal cell pre-treatment in a model of acute kidney rejection.

Authors:  Martina Seifert; Meaghan Stolk; Dietrich Polenz; Hans-Dieter Volk
Journal:  Front Immunol       Date:  2012-07-17       Impact factor: 7.561

3.  Protective effects of astaxanthin against ischemia/reperfusion induced renal injury in mice.

Authors:  Xuefeng Qiu; Kai Fu; Xiaozhi Zhao; Yanting Zhang; Yimin Yuan; Shiwei Zhang; Xiaoping Gu; Hongqian Guo
Journal:  J Transl Med       Date:  2015-01-27       Impact factor: 5.531

4.  Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT-EXT at 7 Years After Transplant.

Authors:  S Florman; T Becker; B Bresnahan; A Chevaile-Ramos; D Carvalho; G Grannas; F Muehlbacher; P J O'Connell; H U Meier-Kriesche; C P Larsen
Journal:  Am J Transplant       Date:  2016-07-12       Impact factor: 8.086

5.  Results of Kidney Transplantation from Expanded Criteria Donors: A Single-Center Experience.

Authors:  B Palkoci; M Vojtko; J Fialová; D Osinová; M Lajčiaková
Journal:  Int J Organ Transplant Med       Date:  2018-02-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.